Bio-Path Holdings to Present at the H.C. Wainwright 22nd Annual Global Investment Conference
Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company
leveraging its proprietary DNAbilize™ liposomal delivery and
antisense technology to develop a portfolio of targeted nucleic
acid cancer drugs, today announced that Peter H. Nielsen, Chief
Executive Officer, will present a corporate overview at the
upcoming virtual H.C. Wainwright 22nd Annual Global Investment
Conference on Wednesday, September 16, 2020 at 11:30 a.m. ET.
A live webcast of the presentation can be accessed under
“Events” in the Media section of the Company’s website at
About Bio-Path Holdings, Inc.
Bio-Path is a biotechnology company developing DNAbilize®, a
novel technology that has yielded a pipeline of RNAi nanoparticle
drugs that can be administered with a simple intravenous
transfusion. Bio-Path’s lead product candidate, prexigebersen
(BP1001, targeting the Grb2 protein), is in a Phase 2 study for
blood cancers and is under consideration by the FDA to commence
Phase 1 studies in solid tumors. This is followed by BP1002,
targeting the Bcl-2 protein, where it will be evaluated in lymphoma
and solid tumors clinical studies.
For more information, please visit the Company's website at
Will O’ConnorStern Investor Relations
Doug Morris Investor Relations Bio-Path Holdings, Inc.